|
|
| | Sulfacarbamide Basic information |
| Product Name: | Sulfacarbamide | | Synonyms: | SULFANILYLUREA;1-(4-Aminobenzenesulfonyl)urea;1-Amino-4-([(aminocarbonyl)amino]sulfonyl)benzene;1-Sulfanilylurea;4-amino-n-(aminocarbonyl)-benzenesulfonamid;4-Amino-N-(aminocarbonyl)benzenesulfonamide;4-Sulfacarbamide;A 435 | | CAS: | 547-44-4 | | MF: | C7H9N3O3S | | MW: | 215.23 | | EINECS: | 208-922-7 | | Product Categories: | SULFAUREA | | Mol File: | 547-44-4.mol |  |
| | Sulfacarbamide Chemical Properties |
| Melting point | 146-148° (slight dec) | | density | 1.4565 (rough estimate) | | refractive index | 1.6630 (estimate) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | DMSO : ≥ 28 mg/mL (130.09 mM) | | pka | pKa 1.78(H2O
t = 25
I = 0.05) (Uncertain);5.42(H2O
t = 25
I = 0.05) (Uncertain) | | Water Solubility | 2.333g/L(20 ºC) | | InChI | InChI=1S/C7H9N3O3S/c8-5-1-3-6(4-2-5)14(12,13)10-7(9)11/h1-4H,8H2,(H3,9,10,11) | | InChIKey | WVAKABMNNSMCDK-UHFFFAOYSA-N | | SMILES | C1(S(NC(N)=O)(=O)=O)=CC=C(N)C=C1 |
| | Sulfacarbamide Usage And Synthesis |
| Description | Sulfacarbamide is a blood sugar-lowering drug, also acting on the vegetative nervous system. | | Chemical Properties | White solid | | Uses | antibacterial | | Uses | Sulfacarbamide-d4 is the labeled analogue of Sulfacarbamide (S688945), an antibiotic which is rapidly absorbed in blister fluid. | | Definition | ChEBI: Sulfacarbamide is a sulfonamide and a member of benzenes. | | World Health Organization (WHO) | Sulfacarbamide, a sulfonamide anti-infective agent, was
introduced in the 1940's for the treatment of bacterial infections. The importance of
sulfonamides has subsequently decreased as a result of increasing bacterial
resistance and their replacement by antibiotics which are generally more active
and less toxic. The Sulfacarbamide are known to cause serious adverse effects
such as renal toxicity, sometimes fatal exfoliative dermatitis and erythema
multiforma and dangerous adverse reactions affecting blood formation such as
agranulocytosis and haemolytic or aplastic anaemia. Sulfacarbamide still remains
available in at least one country for the treatment of urinary infections. | | Mechanism of action | Sulfonylureas bind to and inhibit the ATP-sensitive potassium channels (K) on the pancreatic beta cells. As a result, potassium efflux decreases, and the beta-cell membrane depolarizes. Membrane depolarization causes calcium channels to open, leading to calcium influx and increased intracellular calcium, which stimulates insulin secretion from the pancreatic beta cells. Sulfonylureas cause insulin release regardless of blood glucose levels. |
| | Sulfacarbamide Preparation Products And Raw materials |
|